Studien Malteser St. Franziskus Hospital						**Stand 19.11.2025**
Titel der Studie	**Akronym**	**DRKS Nr/ NCT Nr oder EudraCt Nr.**	**Am Standort initiiert am**	**Status**	**PI am Standort (Name,Email, Telefon)**	**Study Nurse (Name, Email, Telefon)**
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH-1 Mutated AML or MDS/AML Considered Ineligible Chemotherapy	HOVON 173 AMLSG 34-23	2024-512753-24	Apr 26	Mai 26	Nicolai Faber nicolai.faber@malteser.org	Wiebke Hans wiebke.hans@malteser.org 0461-816 2820
Randomized Study to Assess Revumenib in Combination With Azacitidine + Venetoclax in Adult Patients With Newly Diagnosed NPM1 Mutated or KMT2A Rearrnged AML Ineligible for intensiv Chemotherapy	HOVON 177 AMLSG 35-24	2024-512733-32-00	Jan 26	Feb 26	Nicolai Faber nicolai.faber@malteser.org	Wiebke Müller-Siegwardt wiebke.müller-siegwardt@malteser.org 0461 - 816 2830
Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms, and Higher Risk Myelodysplastic Syndrome	AMLSG Bioregister	NCT01252485	Aug 11	Aktiv	Nicolai Faber nicolai.faber@malteser.org	Wiebke Müller-Siegwardt wiebke.müller-siegwardt@malteser.org 0461 - 816 2830
Standard Intensive Chemotherapy versus Intensive Chemotherapy with CPX-351	AMLSG 30-18	EudraCT No:2018-002678-34	Nov 19	Aktiv	Nicolai Faber nicolai.faber@malteser.org , StV Wiebke Sagasser wiebke.sgasser@malteser.org	Wiebke Müller-Siegwardt wiebke.müller-siegwardt@malteser.org 0461 - 816 2830
GMALL-Register und Biomaterialbank Biomaterialsammlung und prospektive Datenerfassung zu Diagnostik, Behandlung und Krankheitsverlauf der ALL des Erwachsenen	GMALL Register	NCT02872987	keine	Aktiv	Nicolai Faber nicolai.faber@malteser.org	Wiebke Hans wiebke.hans@malteser.org 0461-816 2820

A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma	DSMM XVIII HD9	2023-507402-13-00	08..01.2025	Aktiv	Nicolai Faber nicolai.faber@malteser.org ,	Christine Fehrs christine.fehrs@malteser.org 0461-8162530
Nationales Netzwerk Genomisches Medizin Lungenkrebs	nNGM Register	Netzwerkpartner-Nr: 0248	27.08.2019	Aktiv	Nicolai Faber nicolai.faber@malteser.org	Studiensekretariat
A phase II, open-label, single arm study to evaluate the efficacy of Luspatercept in Erythropoiesisstimulating agent naive lower-risk **MDS** patients with or without ring sideroblasts who do not require RBC transfusions	LENNON	EudraCT-No.: 2020-005219-30	Apr 24	Aktiv	Nicolai Faber nicolai.faber@malteser.org	Christine Fehrs christine.fehrs@malteser.org 0461-8162530
A Randomized, Double-Blind, Phase 3 Trial of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer with KRAS G12C Mutation (KRYSTAL-4)	KRYSTAL 04	2024-515698-85	11.06.2025	Aktiv	Nicolai Faber nicolai.faber@malteser.org	Christine Fehrs christine.fehrs@malteser.org 0461-8162530
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer (ARTEMIDE-Lung04)	Artemide-Lung 04	2024-517780-24-00	Jan 26	ab Februar Rekrutierung	Nicolai Faber nicolai.faber@malteser.org	Christine Fehrs christine.fehrs@malteser.org 0461-8162530
A single-arm phase II-study to confirm efficacy and feasibility of tarlatamab treatment in patients with extensive stage small-cell lung cancer with poor performance status	SPACE-T	2025-522437-65-00	Jan 26	ab Februar Rekrutierung	Nicolai Faber nicolai.faber@malteser.org	Wiebke Hans wiebke.hans@malteser.org 0461-816 2820